Aker BioMarine (AKBM) investor relations material

Executive summary

• Revenue reached USD 57.9 million in Q2 2026, up 5% year-over-year, with adjusted EBITDA at USD 12.9 million, down 4% from last year.

• Human Health Ingredients segment delivered record revenues of USD 34.1 million, up 17% year-over-year, with adjusted EBITDA of USD 15.9 million, up 14%.

• Consumer Health Products segment saw revenues decline 6% year-over-year to USD 26.4 million, with adjusted EBITDA at USD 1.1 million.

• Net loss for Q2 was USD 5.4 million, compared to a net loss of USD 14.7 million in Q2 2025.

• Major new contracts secured for Lysoveta (USD 4 million for China) and Superba (U.S. market, expected to be among top customers).

Financial highlights

• Gross margin remained stable overall, though Epion's margin declined due to a new revenue model with Pattern.

• SG&A increased in Human Health Ingredients due to investments, but decreased in Consumer Health Products from Epion cost reductions.

• Cash flow from operations was negative USD 6.3 million in Q2, mainly due to working capital and nutra meal payment.

• Net interest-bearing debt at USD 185 million, up from Q1, mainly due to Nutra settlement.

• Equity ratio at 34%, with total equity of USD 135.9 million.

Outlook and guidance

• Continued strong growth and improved profits expected for Human Health Ingredients.

• Consumer Health Products anticipated to return to modest growth as new product launches are implemented.

• Ongoing preparations for a potential transaction in 2026, with no further updates until process conclusion.

• Lysoveta expected to see a stream of new customers and market expansion, with EU approval anticipated in early 2027.

• Macroeconomic and geopolitical uncertainties may impact energy prices, supply chains, and demand.